|
Fatty acid tertile
|
n
|
Model 11
|
Model 22
|
|---|
|
PUFA
| | | |
|
<65.27%
|
166
|
10.51 (10.05, 10.99)3
|
10.40 (9.98, 10.83)
|
|
65.27–68.11%
|
165
|
10.20 (9.77, 10.65)
|
10.11 (9.73, 10.50)
|
|
≥68.12%
|
165
|
10.04 (9.61, 10.49)
|
10.25 (9.85, 10.66)
|
|
P-trend4
| |
0.17
|
0.66
|
|
n-6 PUFA5
| | | |
|
<60.77%
|
166
|
10.27 (9.81, 10.75)
|
10.19 (9.77, 10.62)
|
|
60.77–64.19%
|
165
|
10.28 (9.85, 10.73)
|
10.27 (9.88, 10.66)
|
|
≥64.20%
|
165
|
10.20 (9.76, 10.68)
|
10.30 (9.89, 10.73)
|
|
P-trend4
| |
0.86
|
0.74
|
|
LA (18:2n-6)
| | | |
|
<52.45%
|
166
|
10.20 (9.75, 10.68)
|
10.21 (9.79, 10.64)
|
|
52.45–56.90%
|
165
|
10.27 (9.84, 10.71)
|
10.23 (9.85, 10.63)
|
|
≥56.91%
|
165
|
10.28 (9.83, 10.75)
|
10.31 (9.90, 10.75)
|
|
P-trend4
| |
0.83
|
0.74
|
|
GLA (18:3n-6)
| | | |
|
<0.44%
|
166
|
10.03 (9.61, 10.48)
|
10.13 (9.74, 10.53)
|
|
0.44–0.66%
|
165
|
10.27 (9.84, 10.72)
|
10.26 (9.88, 10.66)
|
|
≥0.67%
|
165
|
10.45 (10.01, 10.92)
|
10.36 (9.97, 10.77)
|
|
P-trend4
| |
0.20
|
0.43
|
|
DGLA (20:3n-6)
| | | |
|
<0.45%
|
166
|
10.15 (9.71, 10.60)
|
10.15 (9.75, 10.57)
|
|
0.45–0.56%
|
165
|
10.50 (10.06, 10.96)
|
10.55 (10.16, 10.96)
|
|
≥0.57%
|
165
|
10.11 (9.67, 10.57)
|
10.05 (9.64, 10.48)
|
|
P-trend4
| |
0.93
|
0.81
|
|
AA (20:4n-6)
| | | |
|
<6.06%
|
166
|
10.42 (9.98, 10.87)
|
10.34 (9.95, 10.74)
|
|
6.06–7.17%
|
165
|
10.20 (9.77, 10.65)
|
10.23 (9.85, 10.63)
|
|
≥7.18%
|
165
|
10.13 (9.71, 10.57)
|
10.18 (9.79, 10.58)
|
|
P-trend4
| |
0.37
|
0.58
|
|
n-3 PUFA5
| | | |
|
<3.35%
|
166
|
10.73 (10.27, 11.21)
|
10.45 (10.04, 10.88)
|
|
3.35–4.71%
|
165
|
10.25 (9.82, 10.69)
|
10.14 (9.75, 10.54)
|
|
≥4.72%
|
165
|
9.79 (9.36, 10.23)
|
10.16 (9.36, 10.58)
|
|
P-trend4
| |
0.01
|
0.34
|
|
ALA (18:3n-3)
| | | |
|
<0.56%
|
167
|
10.54 (10.10, 11.00)
|
10.25 (10.03, 10.48)
|
|
0.56–0.67%
|
166
|
10.47 (10.04, 10.92)
|
10.25 (10.03, 10.47)
|
|
≥0.68%
|
163
|
9.75 (9.33, 10.18)
|
10.25 (10.03, 10.48)
|
|
P-trend4
| |
0.02
|
0.99
|
|
EPA (20:5n-3)
| | | |
|
<1.66%
|
166
|
10.72 (10.26, 11.20)
|
10.45 (10.03, 10.88)
|
|
1.66–2.79%
|
165
|
10.12 (9.70, 10.55)
|
10.12 (9.75, 10.52)
|
|
≥2.80%
|
165
|
9.93 (9.50, 10.38)
|
10.18 (9.77, 10.60)
|
|
P-trend4
| |
0.02
|
0.40
|
|
DHA (22:6n-3)
| | | |
|
<1.00%
|
166
|
10.73 (10.27, 11.20)
|
10.49 (10.09, 10.91)
|
|
1.00–1.31%
|
165
|
10.09 (9.67, 10.53)
|
10.05 (9.68, 10.44)
|
|
≥1.32%
|
165
|
9.95 (9.52, 10.40)
|
10.21 (9.81, 10.63)
|
|
P-trend4
| |
0.02
|
0.34
|
- Abbreviations: AA Arachidonic acid, ALA A-linolenic acid, CE Cholesterol ester, DGLA Dihomo-γ-linolenic acid, DHA Docosahexaenoic acid, EPA Eicosapentaenoic acid, GLA γ-linolenic acid, LA Linoleic acid, PUFA Polyunsaturated fatty acid.
- 1Adjusted for age (y, continuous), sex and workplace [A (surveyed in July) or B (surveyed in November)].
- 2Adjusted for age (y, continuous), sex, workplace [A (surveyed in July) or B (surveyed in November)], smoking status (non-smoker or smoker), BMI (kg/m2, continuous), alcohol consumption (non-drinker, <20 g/d or ≥20 g/d), occupational physical activity (sedentary work or active work), non-occupational physical activity (0, 0 < to <5 or ≥5 MET-h/wk), serum folate (ng/mL, continuous), vitamin B6 intake (mg, continuous) and vitamin B12 intake (μg/1000 kcal, continuous).
- 3Geometric means (95% confidence interval) of serum homocysteine (nmol/mL).
- 4P-trend values were based on multiple regression analysis, with ordinal numbers 0–2 assigned to tertile categories of each fatty acid.
- 5N-6 PUFA is the sum of LA, GLA, DGLA, and AA; n-3 PUFA is the sum of ALA, EPA, and DHA; PUFA is the sum of n-6 and n-3 PUFA.
